GET DAILY SIGNALSVeradermics (MANE) Analyst Targets Signal +21% Upside to $180
Key Takeaways
- The central stock price target of $180 is the arithmetic mean of seven verified analyst price targets, rounded from roughly $179.57, and sits 21% above the latest price.
- Shares of Veradermics, Incorporated (MANE) closed at $148.44 on November 10, 2026, meaning the target implies about a 21% upside.
- The seven tracked targets range from $150 (Leerink Partners) to $204 (B. Riley and UBS), a wide dispersion typical of a pre-revenue, late-stage biotech.
- The consensus is a Strong Buy or Moderate Buy, with every tracked target carrying a Buy or Outperform rating.
- The strongest support is positive Phase 3 data for lead candidate VDPHL01 and a cash position of roughly $798 million funding operations into 2030; the biggest risks are a multi-billion-dollar valuation for an unapproved drug and notable insider selling.
- For more detail on Major News, Today's Price Move, the Forecast, and Earnings, explore the dedicated Tickeron pages.
- You can also monitor Trending AI Robots to see which AI-driven trading strategies are active in names like MANE.
Analyst Price Targets and Consensus View
Veradermics, Incorporated (MANE) is a dermatologist-founded, late clinical-stage biopharmaceutical company that went public on the NYSE in February 2026 at $17.00 per share. Because the company is pre-revenue, its valuation is driven almost entirely by clinical progress and the market opportunity for its lead asset, an oral, non-hormonal, extended-release minoxidil called VDPHL01 being developed for pattern hair loss. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $180 central target is a calculated mean, not an official published consensus. Averaging seven current analyst price targets — $175 (Citi), $150 (Leerink Partners), $182 (Jefferies), $172 (Needham), $170 (LifeSci Capital), and $204 each from B. Riley and UBS — produces about $179.57, rounded to $180. The low-to-high range of $150 to $204 reflects genuine disagreement about how much of VDPHL01's multi-billion-dollar peak-sales potential is already reflected in the share price.
Analysts are uniformly constructive: all seven tracked targets carry Buy or Outperform ratings, and services such as S&P Global and TipRanks describe the consensus as Strong Buy. Bullish cases emphasize a first-in-decades non-hormonal oral option for hair loss, while the more cautious $150 target reflects concern that the stock has already run far on positive data. One outlier sell-side shop, Weiss Ratings, has published a Sell rating, underscoring that views are not unanimous.
Current Market Position and Path Toward the Target
At a closing price of $148.44, reaching $180 requires roughly a 21% gain — a substantial move, though far smaller than the stock's roughly 350% year-to-date advance from its $32.00 52-week low. Shares sit just below the 52-week high of $152.82, meaning the path toward $180 begins by clearing that prior peak and establishing new highs.
The route would most plausibly run through continued execution on VDPHL01, including regulatory filings and potential approval, rather than near-term financial results. The company reported a third-quarter net loss of about $21.0 million and held roughly $798.4 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which management says funds operations into 2030. With no approved product, revenue remains minimal, so the story hinges on clinical and regulatory milestones.
What Could Support a Move Toward the Target
- Positive Phase 3 data: In Study 304 in men, twice-daily VDPHL01 delivered a 36.4 hairs-per-square-centimeter gain at six months versus 6.6 for placebo, with 85% of patients reporting improved coverage versus 35.3% on placebo. Twelve-month Study 302 results showed gains holding with no new safety signals.
- Differentiated positioning: As an oral, non-hormonal therapy, VDPHL01 would offer an alternative to finasteride, the only approved oral today, which acts hormonally.
- Analyst revisions: Several firms — including Citi, Leerink, Needham, and B. Riley — have raised targets through late 2026, reflecting growing confidence after the Phase 3 readouts.
- Balance-sheet strength: The large cash position reduces near-term dilution risk and supports a lengthy runway.
What Could Prevent the Target From Being Reached
- Valuation: A roughly $6.2 billion market capitalization for a pre-revenue company with one unapproved drug leaves limited margin for error.
- Regulatory and clinical risk: Approval is not guaranteed, and additional trials or delays could compress sentiment.
- Competition: Generic oral minoxidil is already used off-label by dermatologists, which some investors see as a ceiling on pricing power.
- Insider selling: Insiders sold roughly 961,000 shares worth about $103 million over a recent 90-day period, though much occurred under pre-arranged plans.
- Wide target dispersion: A $150-to-$204 range signals that even bulls disagree sharply on fair value.
Technical Levels and Market Structure
Shares trade just below the 52-week high of $152.82, which is the immediate resistance zone; a decisive break above it would leave the stock in price discovery. The 50-day moving average near $118.66 and the 200-day moving average near $97.43 mark progressively deeper support, while the $32.00 IPO-era low and the $17.00 offering price frame how far the stock has already traveled. Given the rapid ascent, the technical structure suggests that any pullback toward the 50-day average would be a key level for investors to watch. From what I see, monitoring these levels with tools like Tickeron’s AI Trend Prediction Engine helps clarify the setup.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may vary. For a clinical-stage company, the relevant catalysts are not quarterly earnings but rather regulatory updates, additional trial data, and analyst revisions. Investors should watch for any FDA filing or approval timelines for VDPHL01, updates on secondary pipeline programs, changes in cash burn, and any new price-target changes from the covering firms. Macro factors such as interest rates matter less here than biotech sentiment and sector risk appetite.
Using AI Tools in My Research
In my analysis of names like MANE, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional layer of perspective. These signals draw on artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that reflect shifting market conditions, technical patterns, and data-driven insights. For a rapidly moving stock in this space, the approach can surface opportunities and highlight trend changes more quickly than manual review alone.
Final Assessment
The $180 central target is a calculated average of seven Buy-rated analyst price targets ranging from $150 to $204, implying about a 21% gain from the $148.44 close. Reaching it would depend primarily on continued execution and regulatory progress for VDPHL01, supported by strong Phase 3 data and a deep cash runway. The principal obstacles are a steep valuation for a pre-revenue company, the possibility of approval delays, and meaningful analyst disagreement about fair value. The path is plausible but not assured; investors should focus on regulatory milestones and analyst revisions rather than any single price figure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Momentum Indicator for MANE turns positive, indicating new upward trend
MANE saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In 13 of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MANE just turned positive on November 10, 2026. Looking at past instances where MANE's MACD turned positive, the stock continued to rise in 7 of 7 cases over the following month. The odds of a continued upward trend are 90%.
MANE moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where MANE advanced for three days, in 42 of 47 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 26 of 28 cases where MANE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for MANE moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In 7 of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MANE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
MANE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.127) is normal, around the industry mean (3.498). P/E Ratio (-55.597) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MANE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MANE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement